345 related articles for article (PubMed ID: 31922462)
21. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
22. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
Abdel Raheem A; Capece M; Kalejaiye O; Abdel-Raheem T; Falcone M; Johnson M; Ralph OG; Garaffa G; Christopher AN; Ralph DJ
BJU Int; 2017 Nov; 120(5):717-723. PubMed ID: 28612401
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of collagenase Clostridium histolyticum in men with ventral curvatures: an updated series.
Larson H; Savage J; Brearton K; Warner R; Ziegelmann M; Kohler T; Trost L
J Sex Med; 2024 Jan; 21(2):169-174. PubMed ID: 38141054
[TBL] [Abstract][Full Text] [Related]
24. Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie's Disease with Calcified Plaques.
Masterson TA; Atuluru P; Zucker I; Molina M; Ibrahim E; Nackeeran S; Kava B; Ramasamy R
Eur Urol Focus; 2023 Jan; 9(1):55-59. PubMed ID: 36272924
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.
Alom M; Sharma KL; Toussi A; Kohler T; Trost L
J Sex Med; 2019 Jun; 16(6):891-900. PubMed ID: 30956106
[TBL] [Abstract][Full Text] [Related]
26. Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease.
Hellstrom WJG; Tan RBW; Liu G
Urology; 2017 Aug; 106():237.e9-237.e14. PubMed ID: 28502596
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD).
Carson CC; Sadeghi-Nejad H; Tursi JP; Smith TM; Kaufman GJ; Gilbert K; Honig SC
BJU Int; 2015 Nov; 116(5):815-22. PubMed ID: 25818264
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of collagenase Clostridium histolyticum in Peyronie's disease following a modified treatment protocol.
García Cruz E; Mercader Barrull C; Camacho Rovira D; Alcaraz Asensio A
Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):215-219. PubMed ID: 33531284
[TBL] [Abstract][Full Text] [Related]
29. Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Anaissie J; Powers MK; Hellstrom WJ; Yafi FA
Drugs Today (Barc); 2015 Aug; 51(8):457-68. PubMed ID: 26380384
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Collagenase
Green B; Flores A; Warner J; Kohler T; Helo S; Trost L
J Urol; 2023 Nov; 210(5):791-802. PubMed ID: 37811752
[TBL] [Abstract][Full Text] [Related]
31. Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.
Goldstein I; Knoll LD; Lipshultz LI; Smith T; Kaufman GJ; McMahon CG
Sex Med; 2017 Jun; 5(2):e124-e130. PubMed ID: 28395998
[TBL] [Abstract][Full Text] [Related]
32. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire.
Hellstrom WJ; Feldman R; Rosen RC; Smith T; Kaufman G; Tursi J
J Urol; 2013 Aug; 190(2):627-34. PubMed ID: 23376705
[TBL] [Abstract][Full Text] [Related]
33. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.
Gelbard M; Lipshultz LI; Tursi J; Smith T; Kaufman G; Levine LA
J Urol; 2012 Jun; 187(6):2268-74. PubMed ID: 22503048
[TBL] [Abstract][Full Text] [Related]
34. Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: Results from a retrospective analysis.
Capece M; Arcaniolo D; Manfredi C; Palmieri A; De Sio M; Verze P; Fusco F; Longo N; Mirone V
Andrologia; 2020 Apr; 52(3):e13527. PubMed ID: 32003061
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.
Nguyen HMT; Anaissie J; DeLay KJ; Yafi FA; Sikka SC; Hellstrom WJG
J Sex Med; 2017 Oct; 14(10):1220-1225. PubMed ID: 28874331
[TBL] [Abstract][Full Text] [Related]
36. Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling.
Fernández-Pascual E; González-García FJ; Angulo J; Cerezo E; Quintana LM; Turo J; Martínez-Ballesteros C; Carballido J; Martínez-Salamanca JI
BJU Int; 2019 Dec; 124(6):1055-1062. PubMed ID: 31033130
[TBL] [Abstract][Full Text] [Related]
37. Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.
Gabrielson AT; Spitz JT; Hellstrom WJG
Sex Med Rev; 2018 Jan; 6(1):143-156. PubMed ID: 28454897
[TBL] [Abstract][Full Text] [Related]
38. At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?
Harvey N; Pearce I
Andrology; 2020 Sep; 8(5):1304-1311. PubMed ID: 32459883
[TBL] [Abstract][Full Text] [Related]
39. Intralesional collagenase
Chung E; Wang J
Investig Clin Urol; 2022 Sep; 63(5):563-568. PubMed ID: 36068002
[TBL] [Abstract][Full Text] [Related]
40. Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study.
Capece M; Cocci A; Russo G; Cito G; Giubilei G; Cacciamani G; Garaffa G; Falcone M; Timpano M; Tasso G; Sessa F; Campi R; Di Maida F; Cai T; Morelli G; Giammusso B; Verze P; Palmieri A; Ralph D; Mirone V; Mondaini N
Andrology; 2018 Jul; 6(4):564-567. PubMed ID: 29733116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
